rs947005337
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PP3_StrongPP5
The NM_015450.3(POT1):c.233T>C(p.Ile78Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000871 in 1,607,628 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000082 ( 0 hom. )
Consequence
POT1
NM_015450.3 missense
NM_015450.3 missense
Scores
10
8
1
Clinical Significance
Conservation
PhyloP100: 5.99
Genes affected
POT1 (HGNC:17284): (protection of telomeres 1) This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 5 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.945
PP5
Variant 7-124870933-A-G is Pathogenic according to our data. Variant chr7-124870933-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 475073.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=2, not_provided=1, Pathogenic=1, Likely_pathogenic=2}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.233T>C | p.Ile78Thr | missense_variant | 7/19 | ENST00000357628.8 | NP_056265.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POT1 | ENST00000357628.8 | c.233T>C | p.Ile78Thr | missense_variant | 7/19 | 2 | NM_015450.3 | ENSP00000350249.3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152138Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
152138
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000162 AC: 4AN: 246852Hom.: 0 AF XY: 0.00000749 AC XY: 1AN XY: 133562
GnomAD3 exomes
AF:
AC:
4
AN:
246852
Hom.:
AF XY:
AC XY:
1
AN XY:
133562
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000824 AC: 12AN: 1455490Hom.: 0 Cov.: 29 AF XY: 0.00000967 AC XY: 7AN XY: 724026
GnomAD4 exome
AF:
AC:
12
AN:
1455490
Hom.:
Cov.:
29
AF XY:
AC XY:
7
AN XY:
724026
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152138Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74312
GnomAD4 genome
AF:
AC:
2
AN:
152138
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74312
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:7Uncertain:1Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Tumor predisposition syndrome 3 Pathogenic:3
Likely pathogenic, no assertion criteria provided | clinical testing | Center of Human Genetics, Hôpital Erasme | - | The variant is rare in gnomADv4 (14/1607628 alleles ; frequency : 0.00087%). Isoleucine 78 is an amino acid that seems very conserved in evolution except in zebrafish. The variant has been reported in an individual with multiple primary melanomas (PMID: 24686846), in several families with melanoma (PMID: 30586141_2018) and in an individual with 2 melanomas and thyroid cancer (PMID: 30451293_2019). This variant is located in the DNA binding domain of POT1 and was recently shown to impair the ability of POT1 to bind to telomeres (PMID:30586141_2018). The patient's phenotype and family history are compatible with the pathology associated with POT1 gene. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 26, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 78 of the POT1 protein (p.Ile78Thr). This variant is present in population databases (no rsID available, gnomAD 0.03%). This missense change has been observed in individuals with clinical features consistent with POT1-related conditions (PMID: 24686846, 30586141, 34193977; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 475073). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POT1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects POT1 function (PMID: 30586141). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 08, 2023 | Observed in individuals with multiple primary melanomas and/or with familial melanoma; however, several unaffected carriers were also identified (PMID: 24686846, 30451293, 37140166, 36876055); Observed in individuals with lymphoid or myeloid malignancies, as well as individuals with thyroid cancer (PMID: 34193977, 37140166); Published functional studies demonstrate a damaging effect: disrupted telomere binding and telomere elongation (PMID: 37140166, 30586141); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24686846, 30451293, 32015491, 31259407, Offin_2020_Abstract, 32155570, 34648949, 32172474, 32987645, 34193977, 36624550, 28393830, 36876055, 37140166, 30586141) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 15, 2023 | The POT1 c.233T>C (p.Ile78Thr) variant has been reported in the published literature in individuals with melanoma (PMID: 37140166 (2023), 36876055 (2023), 30586141 (2019), 30451293 (2019), 24686846 (2014)). This variant has also been identified in an individual with chronic lymphocytic leukemia (PMID: 34193977 (2021)). In addition, this variant has been shown to have a deleterious effect on POT1 protein function (PMID: 37140166 (2023), 30586141 (2019)). The frequency of this variant in the general population, 0.000016 (4/246852 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as likely pathogenic. - |
Long telomere syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | The Telomere Center at Johns Hopkins, Johns Hopkins University School of Medicine | Aug 01, 2022 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 06, 2024 | The p.I78T variant (also known as c.233T>C), located in coding exon 3 of the POT1 gene, results from a T to C substitution at nucleotide position 233. The isoleucine at codon 78 is replaced by threonine, an amino acid with similar properties. This alteration has been observed in multiple individuals with a personal and/or family history that is consistent with POT1-related disease (Wong K et al. JAMA Dermatol, 2019 05;155:604-609; Potrony M et al. Br J Dermatol, 2019 07;181:105-113; Goldstein AM et al. JAAD Int, 2023 Jun;11:43-51; Shi J et al. Nat. Genet. 2014 May;46:482-6; DeBoy EA et al. N Engl J Med, 2023 May; Abu Shtaya A et al. Genes (Basel), 2024 Mar;15; Ambry internal data). However, this variant has also been identified in individuals without melanoma or other POT1 related tumors (Ambry internal data). This alteration was also identified in an individual diagnosed with CML and a second individual diagnosed with CLL (Lim TL et al. Leukemia, 2022 01;36:283-287). Haplotype analysis performed in unrelated carriers of p.I78T identified a common haplotype, suggestive of a founder event (Wong K et al. JAMA Dermatol, 2019 05;155:604-609). Multiple in vitro functional studies indicated that the p.I78T variant was unable to bind telomeres compared to wild type, resulting in elongated telomeres following ectopic expression (Wong K et al. JAMA Dermatol, 2019 05;155:604-609; DeBoy EA et al. N Engl J Med, 2023 May). Direct measurements from patient cells also showed longer telomeres as compared to controls (DeBoy EA et al. N Engl J Med, 2023 May). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Mar 29, 2018 | - - |
Melanoma, cutaneous malignant, susceptibility to, 1 Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Uncertain significance and reported on 03-23-2018 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;.
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D
MetaSVM
Uncertain
T
MutationAssessor
Uncertain
M;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D
REVEL
Pathogenic
Sift
Uncertain
D;D
Sift4G
Pathogenic
D;.
Polyphen
D;.
Vest4
MutPred
Gain of methylation at R80 (P = 0.0588);Gain of methylation at R80 (P = 0.0588);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at